EnzymeRx
Paramus, New Jersey, United States
About EnzymeRx
EnzymeRx! a private, clinical stage biotechnology company developing uricase-PEG 20 for the treatment of resistant and refractory gout and related indications in which hyperuricemia plays a causative role. Our patented formulation of pegylated uricase is designed to have a long half life as well as reduced immunogenicity.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $14.0M
- Last round: Series Unknown (May 2008)
- Website: enzymerx.com
- Phone: +1 201-843-4424
Industries & Categories
Biotechnology, Health Diagnostics, Therapeutics
Canonical: https://fsome.com/organization/enzymerx-2531743 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.